Pharmaleaf (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 18-07-2024
- Paid Up Capital ₹ 1.00 M
as on 18-07-2024
- Company Age 18 Year, 24 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.50 M
as on 18-07-2024
- Revenue -32.47%
(FY 2023)
- Profit -76.70%
(FY 2023)
- Ebitda -80.82%
(FY 2023)
- Net Worth 50.37%
(FY 2023)
- Total Assets 83.74%
(FY 2023)
About Pharmaleaf (India)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.50 M.
Mohammed Khaleeli, Shenaz Khaleeli, Ain Khaleeli, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232KA2006PTC041173
- Company No.
041173
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Dec 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Pharmaleaf (India) Private Limited offer?
Pharmaleaf (India) Private Limited offers a wide range of products and services, including Content Writing Service, Technical Writing Service, Company Law & Labour Law Consultants, Statutory Compliance Services, Project Management.
Who are the key members and board of directors at Pharmaleaf (India)?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shenaz Khaleeli  | Director | 11-Dec-2006 | Current |
| Mohammed Khaleeli | Director | 11-Dec-2006 | Current |
| Ain Khaleeli | Director | 25-Sep-2021 | Current |
| Mohammed Khaleeli | Director | 25-Sep-2021 | Current |
Financial Performance of Pharmaleaf (India).
Pharmaleaf (India) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 32.47% decrease. The company also saw a substantial fall in profitability, with a 76.7% decrease in profit. The company's net worth Soared by an impressive increase of 50.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmaleaf (India)?
In 2023, Pharmaleaf (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 02 Jul 2009 | ₹2.50 M | Open |
How Many Employees Work at Pharmaleaf (India)?
Pharmaleaf (India) has a workforce of 33 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmaleaf (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmaleaf (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
